| Product Name |
SARS-CoV-2 Spike Glycoprotein RBD mRNA, South Africa Variant |
| Description |
This modified mRNA encodes the South African variant of the spike glycoprotein receptor binding domain (RBD, Arg319-Phe541) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). This RBD mutant has K417N, E484K and N501Y mutations in the S glycoprotein RBD as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416).
|
| Features |
- 5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
- 5’-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence
- Codon Optimization: Human
- Mutations: K417N, E484K and N501Y
- Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP
- 3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.
- PolyA: 180 nt
|
Sequence |
Available upon request.
|
| Application |
Animal Vaccine Research (Not for human use) |
| Concentration |
~1 μg/μl |
| Transfection Protocol |
Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol |
| QC |
Agarose gel electrophoresis |
| Shipping |
Dry ice |
| Storage |
-80 oC |